Trouble reading this email? View it in your browser
European Federation of Pharmaceutical industries and associations

EFPIA Newsletter 24 January 2019


Future-proofing EU competitiveness by limiting the negative impact of the SPC manufacturing waiver

A blog by Nathalie Moll, EFPIA Director General

Every new treatment, new diagnostic or medical device starts with the spark of an idea. Protecting that spark through the long and complex process of research, development and licensing then managing its introduction into healthcare systems is the foundation of almost every advance in patient care.

As a scientist and a passionate advocate for Europe’s research and development community, I am deeply concerned about the potential shift in the balance between Europe being at the cutting edge of medical innovation and Europe choosing to compete with China and India in manufacturing low cost, patent-expired medicines. At EFPIA, we have laid out our perspective on the importance of Europe’s intellectual property framework, in particular around the SPC. Read more




Europe’s economic and Intellectual Property Crossroads
23 January 2019

We are at a crossroads between a future based on science, innovation and access for patients to cutting edge treatments... Read more




The EFPIA Manifesto: A vision to build a healthier future for Europe
The research-based pharmaceutical sector is pleased to share its vision and proposals on how to build a healthier future... Read more

Innovative Medicines Initiative (IMI): Collaborating to improve health across Europe
IMI is the world’s largest public-private partnership in health which provides a collaborative platform for companies,... Read more




EU Ecosystem For Monitoring Of Post-Licensure Vaccine Benefit And Risk: From ADVANCE To VAC4EU...
06 March 2019 (Brussels)

An IMI's multi stakeholder conference Read more

ICHOM conference 2019: Redefining value through patient centered outcomes
02 May 2019 (Rotterdam, The Netherlands)

The world-leading event for providers, life sciences and industry on value-based healthcare Read more


What we are reading


Open access drug development tools feature in new IMI2 Call for proposals
On 22 January 2019 (Innovative Medicines Initiative (IMI))

New open access tools for drug development, obesity, and the environmental impacts of medicines are the focus of a new... Read more

Discussion heats up over stockpiling of generic drugs under patent protection
On 21 January 2019 (Euractiv)

European Federation of Pharmaceutical Industries and Associations (EFPIA) insists that to allow the stockpiling of generic... Read more